145 related articles for article (PubMed ID: 37941740)
21. Gynecologic oncologists involvement on ovarian cancer standard of care receipt and survival.
Rim SH; Hirsch S; Thomas CC; Brewster WR; Cooney D; Thompson TD; Stewart SL
World J Obstet Gynecol; 2016; 5(2):187-196. PubMed ID: 29520338
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
23. Impact of Medicaid expansion on women with gynecologic cancer: a difference-in-difference analysis.
Albright BB; Nasioudis D; Craig S; Moss HA; Latif NA; Ko EM; Haggerty AF
Am J Obstet Gynecol; 2021 Feb; 224(2):195.e1-195.e17. PubMed ID: 32777264
[TBL] [Abstract][Full Text] [Related]
24. Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study).
Shoji T; Takatori E; Nagasawa T; Kagabu M; Baba T; Shigeto T; Matsumura Y; Shimizu D; Terada Y; Seino M; Ohta T; Nagase S; Shigeta S; Tokunaga H; Shimada M; Kaiho-Sakuma M; Furukawa S; Soeda S; Watanabe T; Takahashi F; Yokoyama Y
Int J Clin Oncol; 2022 Dec; 27(12):1874-1880. PubMed ID: 36214925
[TBL] [Abstract][Full Text] [Related]
25. Primary treatment of advanced ovarian cancer: how does the 'real world' practice?
Craig AD; Garcia E; Peters PN; Chen LM; Chapman JS
Future Oncol; 2021 Dec; 17(34):4687-4696. PubMed ID: 34435878
[TBL] [Abstract][Full Text] [Related]
26. A look at the gynecologic oncologist workforce - Are we meeting patient demand?
Ackroyd SA; Shih YT; Kim B; Lee NK; Halpern MT
Gynecol Oncol; 2021 Nov; 163(2):229-236. PubMed ID: 34456058
[TBL] [Abstract][Full Text] [Related]
27. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Clamp AR; James EC; McNeish IA; Dean A; Kim JW; O'Donnell DM; Gallardo-Rincon D; Blagden S; Brenton J; Perren TJ; Sundar S; Lord R; Dark G; Hall M; Banerjee S; Glasspool RM; Hanna CL; Williams S; Scatchard KM; Nam H; Essapen S; Parkinson C; McAvan L; Swart AM; Popoola B; Schiavone F; Badrock J; Fananapazir F; Cook AD; Parmar M; Kaplan R; Ledermann JA
Lancet Oncol; 2022 Jul; 23(7):919-930. PubMed ID: 35690073
[TBL] [Abstract][Full Text] [Related]
28. Gynecologic oncologists and ovarian cancer treatment: avenues for improved survival.
Stewart SL; Rim SH; Richards TB
J Womens Health (Larchmt); 2011 Sep; 20(9):1257-60. PubMed ID: 21819252
[TBL] [Abstract][Full Text] [Related]
29. Influence of the gynecologic oncologist on the survival of ovarian cancer patients.
Chan JK; Kapp DS; Shin JY; Husain A; Teng NN; Berek JS; Osann K; Leiserowitz GS; Cress RD; O'Malley C
Obstet Gynecol; 2007 Jun; 109(6):1342-50. PubMed ID: 17540806
[TBL] [Abstract][Full Text] [Related]
30. Surgical cytoreduction for recurrent epithelial ovarian cancer.
Al Rawahi T; Lopes AD; Bristow RE; Bryant A; Elattar A; Chattopadhyay S; Galaal K
Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD008765. PubMed ID: 23450588
[TBL] [Abstract][Full Text] [Related]
31. Optimal primary surgical treatment for advanced epithelial ovarian cancer.
Elattar A; Bryant A; Winter-Roach BA; Hatem M; Naik R
Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD007565. PubMed ID: 21833960
[TBL] [Abstract][Full Text] [Related]
32. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T; Komiyama S; Kigawa J; Tanabe H; Kato K; Itamochi H; Fujiwara H; Kamiura S; Hamano T; Sugiyama T;
BMC Cancer; 2018 Jul; 18(1):771. PubMed ID: 30064406
[TBL] [Abstract][Full Text] [Related]
33. The Effect of Gynecologic Oncologist Availability on Ovarian Cancer Mortality.
Stewart SL; Cooney D; Hirsch S; Westervelt L; Richards TB; Rim SH; Thomas CC
World J Obstet Gynecol; 2014 May; 3(2):71-77. PubMed ID: 26478860
[TBL] [Abstract][Full Text] [Related]
34. Adherence of Primary Care Physicians to Evidence-Based Recommendations to Reduce Ovarian Cancer Mortality.
Stewart SL; Townsend JS; Puckett MC; Rim SH
J Womens Health (Larchmt); 2016 Mar; 25(3):235-41. PubMed ID: 26978124
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of follow-up strategies for women with epithelial ovarian cancer following completion of primary treatment.
Zachou G; El-Khouly F; Dilley J
Cochrane Database Syst Rev; 2023 Aug; 8(8):CD006119. PubMed ID: 37650760
[TBL] [Abstract][Full Text] [Related]
36. Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US.
Liao CI; Chow S; Chen LM; Kapp DS; Mann A; Chan JK
Gynecol Oncol; 2018 May; 149(2):318-323. PubMed ID: 29514737
[TBL] [Abstract][Full Text] [Related]
37. Interventions for the treatment of borderline ovarian tumours.
Faluyi O; Mackean M; Gourley C; Bryant A; Dickinson HO
Cochrane Database Syst Rev; 2010 Sep; 2010(9):CD007696. PubMed ID: 20824864
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
[TBL] [Abstract][Full Text] [Related]
39. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
[TBL] [Abstract][Full Text] [Related]
40. Factor Analysis of Health Care Access With Ovarian Cancer Surgery and Gynecologic Oncologist Consultation.
Gupta A; Chen Q; Wilson LE; Huang B; Pisu M; Liang M; Previs RA; Moss HA; Ward KC; Schymura MJ; Berchuck A; Akinyemiju TF
JAMA Netw Open; 2023 Feb; 6(2):e2254595. PubMed ID: 36723938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
